India's 6 Health Startups Head to France With New Cures

India is building medicines the world has never seen, and six startups are about to prove it on the global stage.

This June, a hand-picked group of Indian healthcare founders will showcase their work at Bharat Innovates 2026 in Nice, France. Between them, they've created India's first CAR-T cancer therapy, AI that guides surgeons in real time, a 24-hour test for deadly infections, and a blood test for Parkinson's disease that doesn't exist anywhere else.

The Ministry of Education chose these companies because they represent a fundamental shift. India is moving from treating disease late to catching it early, and doing it with solutions built for problems the West doesn't face.

Dr. Vinayak S Rengan, founder of Curium Life, puts it plainly. Ninety-five percent of surgeries in India don't happen in top hospitals, so his AI acts like a parking assist for any surgeon who needs expert judgment mid-operation.

Shirish Arya's company, ImmunoACT, developed NexCAR19, India's first homegrown CAR-T cell therapy for blood cancers. It costs far less than imported versions and is already approved by regulators. They're now working on solid tumors.

Dr. Anirvan Chatterjee's startup, HaystackAnalytics, uses gene sequencing and AI to identify infections and drug resistance in critically ill patients within 24 hours. The standard wait is five to 15 days.

Professor Samir K Maji from Amyscan Healthcare has a blood test for Parkinson's that runs at 90% accuracy in a field where no simple confirmatory test exists. Professor Manoj Gopalkrishnan's Algorithmic Biologics turns the body's molecular signals into usable data. And Markandeya Gorantla's ATGC Biotech replaces chemical pesticides with pheromones that disrupt insect mating, work now expanding through an Indo-Israeli venture.

What ties them together is necessity. India's disease patterns don't match Western textbooks. Gallbladder cancer spikes along the Gangetic belt. Gastric cancer is common in Tamil Nadu. A leukemia drug that works in Western patients barely helps Indian ones because of a mutation rarely seen elsewhere.

Gorantla published that finding years ago. The conclusion remains the same today: genomics built on European or American data only takes India so far.

The Ripple Effect

The real power here isn't just medical. It's about democratizing expertise. When surgical AI can give any doctor access to world-class decision-making, outcomes improve everywhere. When genomics gets solved for 1.4 billion people, the lessons scale globally.

India's government is backing this shift hard. The BioE3 policy, approved in August 2024, unlocked serious funding for bio-manufacturing as part of a push toward a $300 billion bio-economy by 2030. France represents the next door: European partners, co-development opportunities, and access to markets hungry for innovation.

Life expectancy in India has doubled since Independence, climbing from around 35 years to roughly 70 today. These six companies are working on the next leap.